Scinai Immunotherapeutics Ltd (NASDAQ:SCNI) — Market Cap & Net Worth
Market Cap & Net Worth: Scinai Immunotherapeutics Ltd (SCNI)
Scinai Immunotherapeutics Ltd (NASDAQ:SCNI) has a market capitalization of $2.26 Million ($2.26 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29555 globally and #5769 in its home market, demonstrating a 55.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scinai Immunotherapeutics Ltd's stock price $0.71 by its total outstanding shares 3187679 (3.19 Million). Analyse SCNI operating cash flow to see how efficiently the company converts income to cash.
Scinai Immunotherapeutics Ltd Market Cap History: 2015 to 2026
Scinai Immunotherapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.26 Billion to $2.26 Million (-45.08% CAGR).
Index Memberships
Scinai Immunotherapeutics Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #882 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2808 of 3165 |
Weight: Scinai Immunotherapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scinai Immunotherapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scinai Immunotherapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
16.20x
Scinai Immunotherapeutics Ltd's market cap is 16.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.22x
Scinai Immunotherapeutics Ltd's market cap is 2.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $10.66 Million | $658.00K | $4.80 Million | 16.20x | 2.22x |
Competitor Companies of SCNI by Market Capitalization
Companies near Scinai Immunotherapeutics Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Scinai Immunotherapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Scinai Immunotherapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Scinai Immunotherapeutics Ltd's market cap moved from $1.26 Billion to $ 2.26 Million, with a yearly change of -45.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.26 Million | -0.29% |
| 2025 | $2.27 Million | -78.71% |
| 2024 | $10.66 Million | -43.78% |
| 2023 | $18.97 Million | -79.90% |
| 2022 | $94.36 Million | -87.40% |
| 2021 | $749.10 Million | -16.37% |
| 2020 | $895.74 Million | -69.75% |
| 2019 | $2.96 Billion | +94.76% |
| 2018 | $1.52 Billion | -11.01% |
| 2017 | $1.71 Billion | +60.00% |
| 2016 | $1.07 Billion | -15.40% |
| 2015 | $1.26 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Scinai Immunotherapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.26 Million USD |
| MoneyControl | $2.26 Million USD |
| MarketWatch | $2.26 Million USD |
| marketcap.company | $2.26 Million USD |
| Reuters | $2.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's… Read more